Overview 

AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange, GENIE) is a non-profit, contract research organization (CRO) wholly owned by the AACR. GENIE supports industry partners throughout the entire drug development lifecycle – from preclinical discovery to regulatory post-market activities – by delivering market-leading quality real-world data (RWD) solutions and tailored research partnerships. GENIE is built on two core components:  

1. The GENIE Registry – A premier real-world clinico-genomic data repository
2. The GENIE Consortium – A collaborative network of 20 leading, international academic cancer centers. 

Why Choose GENIE? 

GENIE offerings extend to every stage of drug development: 

• Excellent Data Quality – Clinico-genomic RWD derived from international cancer centers 
• Expert Research Network – Collaborative ecosystem of 20 leading cancer institutions 
• End-to-End Drug Development Support – From discovery to post-market surveillance 
• Regulatory-Grade Evidence Generation – RWD to generate evidence for regulatory filings 

By bridging the gap between clinical research and real-world application, GENIE offers flexible partnership opportunities for industry leaders seeking high-quality, real-world oncology data to support scientific innovation and regulatory success.  

To learn more about our collaborative opportunities, please email genieinfo@aacr.org. We look forward to discussing potential partnerships and exploring how we can work together.